Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
101 hedge funds and large institutions have $2.39B invested in Juno Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 101 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$234M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$108M |
| 3 |
VM
VHCP Management
New York
|
+$78.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$51.5M |
| 5 |
Temasek Holdings
Singapore
|
+$41M |
Top Sellers
JUNO Hedge Fund Activity: Q4 2014 in Review
101 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q4 2014, worth a combined $2.39B.
Buyers outnumbered sellers: 101 funds opened new JUNO positions and 0 closed out — a net gain of 101 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $234M.
- 101 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $2.39B of Juno Therapeutics, Inc. stock for Q4 2014.
- 101 funds opened new Juno Therapeutics, Inc. positions in Q4 2014 and 0 closed out, a net change of +101 holders.
- The largest Juno Therapeutics, Inc. buyer in Q4 2014 was Fidelity Investments, an estimated $234M added.
Based on aggregated 13F filings for Q4 2014.